EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Inclusion Criteria:

Histologically or cytologically confirmed adenocarcinoma of the prostate (Gleason score)
Bisphosphonate treatment
Stable, ongoing adequate testosterone suppression proven by hypogonadal levels of testosterone (less than or equal to) <= 50 nanogram per deciliter [ng/dL]) for subjects without surgical castration (luteinizing hormone-releasing hormone antagonists and agonists)
Other protocol defined inclusion criteria could apply

Exclusion Criteria:

Prior chemotherapy, biologic therapy (targeted therapy), or any experimental therapy for mCRPC
Chronic and ongoing treatment with opioids
Acute pathologic fracture, spinal cord compression, or hypercalcemia at Screening
Visceral metastasis, brain metastasis
Radiotherapy to bone lesions and/or orthopedic surgery for pathologic fractures. Any kinds of major elective surgery within 30 days prior to trial treatment
Other protocol defined exclusion criteria could apply